Dr Anneli Hällgren has more than 25 years of experience from drug development within several therapeutic areas and with emphasis on preclinical development strategies and on nonclinical regulatory documentation. During her career, Dr Hällgren has been responsible for documenting the nonclinical safety of numerous drugs entering clinical trials, several of which have reached the market. Her career began at AstraZeneca, where she worked as a safety pharmacologist and preclinical project manager. Since then, she has held executive development positions at companies such as KaroBio, Biolipox and Melacure Therapeutics and is currently acting as an independent consultant in preclinical drug development. 

Dr Hällgren holds an M.Sc. in Pharmacy and a Ph.D. in Physiology from the Medical Faculty at Uppsala University.